Rybelsus (semaglutide)." Novo Nordisk Pharmaceuticals Pty Ltd 4
Myth: Everyone Gets Severe Nausea Reality: While nausea is common, most cases are mild and transient
The 2025 Am J Gastroenterology: Better Outcomes, Not Worse A separate multicenter analysis, published in American Journal of Gastroenterology (May 2025), extended the question beyond risk to outcomes
total body lean mass change: bimagrumab 30 mg/kg, +2.5%
For ketamine specifically, the cross-reactivity pattern is much narrower than for other drugs
Important safety considerations include risks of pancreatitis, gallbladder disease, diabetic retinopathy progression with rapid blood glucose improvement, and dehydration from gastrointestinal side effects